Metropolis Healthcare Ltd
NSE: METROPOLIS BSE: 542650Healthcare
Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.
₹509
52W: ₹400 — ₹600
PE 64.9 · Book ₹64 · +695% vs bookMarket Cap₹10,561 Cr
Stock P/E64.9Price to Earnings
ROCE16.8%Return on Capital
ROE13.1%Return on Equity
Div. Yield0.39%Face Value ₹2
Weaknesses
- −Stock is trading at 8.00 times its book value
- −The company has delivered a poor sales growth of 10.8% over past five years.
- −Company has a low return on equity of 11.8% over last 3 years.
- −Dividend payout has been low at 5.90% of profits over last 3 years
Shareholding Pattern
Promoters48.86%
FIIs10.43%
DIIs35.8%
Public4.92%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 49.62% | 49.43%▼0.2 | 49.4%▼0.0 | 48.89%▼0.5 | 48.89% | 48.89% | 48.87%▼0.0 | 48.86%▼0.0 |
| FIIs | 18.25% | 18.56%▲0.3 | 16.73%▼1.8 | 15.29%▼1.4 | 12.83%▼2.5 | 12.52%▼0.3 | 11.68%▼0.8 | 10.43%▼1.3 |
| DIIs | 27.42% | 28.02%▲0.6 | 30%▲2.0 | 30.3%▲0.3 | 32.4%▲2.1 | 33.1%▲0.7 | 34.73%▲1.6 | 35.8%▲1.1 |
| Public | 4.69% | 3.98%▼0.7 | 3.86%▼0.1 | 5.51%▲1.6 | 5.87%▲0.4 | 5.48%▼0.4 | 4.69%▼0.8 | 4.92%▲0.2 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 269 | 292 | 286 | 322 | 297 | 312 | 324 | 356 | 335 | 352 |
| Expenses | 211 | 218 | 218 | 240 | 232 | 259 | 247 | 264 | 255 | 262 |
| Operating Profit | 59 | 74 | 68 | 82 | 65 | 53 | 77 | 91 | 80 | 90 |
| OPM % | 22% | 25% | 24% | 26% | 22% | 17% | 24% | 26% | 24% | 26% |
| Net Profit | 27 | 32 | 31 | 42 | 27 | 24 | 36 | 47 | 32 | 43 |
| EPS ₹ | 1.3 | 1.55 | 1.53 | 2.06 | 1.34 | 1.15 | 1.72 | 2.25 | 1.55 | 2.09 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹1,365Cr, up 12.2% YoY. OPM at 25%.
Debt Position
Borrowings at ₹152Cr. Debt-to-equity ratio: 0.12x. Healthy balance sheet.
Institutional Flow
DIIs: 35.8% (+20.91pp change). FIIs: 10.43% (-15.23pp change). Promoters hold 48.86%.
Margin & Efficiency
ROCE declining from 22% (Mar 2015) to 0% (Mar 2026). Working capital days: 0.
Valuation
PE 64.9x with 16.8% ROCE. Price is 695% above book value of ₹64. Dividend yield: 0.39%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 14 May - Audio recording of Q4 FY26 earnings conference call posted on company website.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 14 May
- General Update 14 May - Revised FY26 results issued after correcting prior-year profit figure; auditors gave unmodified opinion.
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 13 May - Metropolis Healthcare reported Q4FY26 revenue ₹425 Cr, EBITDA ₹108 Cr, PAT ₹51 Cr; approves ₹1 dividend.
- Announcement under Regulation 30 (LODR)-Investor Presentation 13 May - Investor Presentation for the quarter ended March 31, 2026
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse